Endocrine complications of beta-thalassemia major patients—Cross-sectional study

Attanayaka Mudiyanselage Dilhara Sewwandi Karunaratna, Jamburagoda Gamage Shirani Ranasingha, Rasnayaka Mudiyanselage Mudiyanse

ABSTRACT

Aims: To evaluate the prevalence of endocrine complications in beta thalassaemia major patients in one of thalassaemia treatment units in Sri Lanka. Methods: The patients (n = 40) aged >2 years admitted to the Teaching Hospital Peradeniya during the period of December 2013 to December 2014, under the treatment of iron chelation drugs were recruited for the study. The patients were interviewed for the sociodemographic variables and the data regarding endocrine complications were gathered from medical records. Anthropometric (height and weight) measurers and pubertal status were assessed by a qualified medical officer. The data were statistically analyzed by SPSS version 21. Results: The mean age of the patients was 10.97±5.9 years (range 2–20). The most common endocrine complication was a pubertal delay (53%). The prevalence of short stature, hypothyroidism, diabetes mellitus, and hypoparathyroidism were 50%, 10%, 5%, and 2.5%, respectively. All the patients with endocrine complications were older children (>10-year-olds). Conclusion: Endocrine complications were common among the studied group of beta-thalassaemia major patients and it is related to progression of age. Regular assessment of endocrine function is imperative in the proper management of beta-thalassemia major patients.

Keywords: Beta-thalassemia major, Endocrine complications, Short stature

INTRODUCTION

Beta-thalassemia major is an inherited disorder characterized by absence or inadequacy of beta globin chain synthesis. It is the most common monogenic hereditary hemoglobin disorder, which poses a major health burden in Sri Lanka [1].

Globally, 300,000–400,000 babies are born with sickle cell disease and thalassemia. According to most recent studies, it is estimated that 1.5% of global population are carriers of beta thalassemia and approximate number
of annual births of severe forms of beta thalassemia ranges from 50,000 to 60,000 [2].

The national incidence of 60–80 cases per year [3] together with the estimated life span of 20–25 years has resulted in a patient load exceeding 2000 patients. The prevalence of beta thalassemia trait among Sri Lankan population varies in different parts of the country from 1% to 5% [1].

Thalassemia patients suffer from chronic anemia due to hemolysis and ineffective erythropoiesis. Therefore, lifelong blood transfusion therapy is mandatory. Studies done in America, Pakistan, and Egypt showed high serum ferritin levels among thalassemia patients [4–6]. Therefore, despite advances in novel iron chelation therapy regimes, iron overload is the most common secondary complication among thalassemia patients.

Endocrine complications, such as hypogonadism, hypothyroidism, hypoparathyroidism, and pancreatic and adrenal insufficiency, are frequently observed among the thalassemia patients [7, 8]. Delayed puberty, growth retardation, diabetes, and hypogonadism are among the most prevalent manifestations of endocrinopathies. Hypothyroidism also observed frequently among thalassemia patients [9, 10]. The rate of diabetes among thalassemia patients has been reported to range from 2.3% to 24% [11, 12]. Hypoparathyroidism is known to occur rarely among thalassemia patients [11, 12].

Iron toxicity in endocrine glands mainly attributes to endocrinopathies among thalassemia patients [8]. Therefore, most of the time endocrine abnormalities are diagnosed during the second decade of life with the progression of iron deposition. Apart from iron toxicity, other factors including chronic anemia, zinc deficiency, and toxicity of iron chelating agents play a causative role in endocrinopathies.

Although, the prevalence of endocrinopathies among beta-thalassemia major patients were well studied in developed countries data of developing countries is limited. However, due to differences in healthcare standards and genetic makeup, national-level statistics of endocrinopathies might differ from those of developed countries. Moreover, prompt diagnosis and treatment of endocrine complications are imperative to improve the life span and quality of life of beta thalassemia major patients.

Therefore, the aim of this study is to evaluate the frequency of endocrine complications in a group of beta-thalassemia major patients at Teaching Hospital, Peradeniya in Sri Lanka and to identify the associated factors of endocrinopathies.

**MATERIALS AND METHODS**

**Study setting**

This is a cross-sectional study conducted on endocrine complications of the transfusion dependent beta-thalassemia major patients under iron chelation therapy at one of the thalassemia treating unit at Teaching Hospital, Peradeniya in Sri Lanka during the period from January to December, 2014. The ethical approval was obtained from ethical review committee, Faculty of Medicine, University of Peradeniya (2013/EC/43).

**Subjects**

A total of 40 patients aged >2-year-olds with confirmed diagnosis of beta-thalassemia major under iron chelation therapy were recruited to the study. The diagnosis of beta thalassemia major disease was made by reduced or absent HbA, elevated levels of HbA2, and increased HbF which is detected by haemoglobin electrophoresis and high performance liquid chromatography (HPLC). The patients with abnormal liver and renal functions and acute infections were excluded from the study. The written consent was obtained from the guardians of the patients and controls before recruitment.

**Methodology**

A standardized and validated questionnaire was used by the interviewer to gather information from all the patients during their hospital stay for regular blood transfusion. The medical histories were obtained from hospital files. The questionnaire was pretested with few patients in the pediatric unit of Peradeniya Teaching Hospital to ensure its feasibility and accuracy. Delayed puberty was diagnosed in boys by the absence of testicular development by age of 14 years and in girls by the absence of breast development by the age of 13 years respectively [13, 14].

Hypoparathyroidism was diagnosed by low levels of serum calcium and high serum phosphates levels. Diabetes mellitus was screened by postprandial blood sugar and diagnosis was confirmed by the fasting blood glucose level more than 120 g/dL. Hypothyroidism was diagnosed by a high serum thyroid stimulating hormone (TSH) level.

Blood samples (5 mL) were collected and centrifuged to separate serum. The serum was stored in −60°C until analysis.

Serum ferritin level was analyzed by enzyme linked immunosorbent assay (ELISA) kits (Fortress Diagnostics, Antrim, United Kingdom).

**Measurement of anthropometric parameters**

We followed the methods of Karunaratna et al. 2017 [15]. Height of each patient was measured using a standard stadiometer. Weight was measured with light clothes using a standardized digital bathroom body weight scale. The Z-scores for height and body mass index (BMI) were calculated by standard equations provided by World Health Organization [16].
Table 1: The comparison of clinical variables between two groups (based on serum ferritin concentration) in beta-thalassemia major

| Clinical parameter                  | Patients with one or more endocrine complications | Patients with none of the endocrine complications studied | p-value*  |
|------------------------------------|---------------------------------------------------|----------------------------------------------------------|-----------|
| Mean age (years)                   | 17.70±2.36                                        | 9.03±5.22                                                | 0.00**    |
| Duration of blood transfusion (months) | 203.4±26.61                                       | 103.7±63.34                                             | 0.00**    |
| Blood transfusion volume (mL/kg/year) | 298.27±104.72                                    | 251.88±59.99                                           | 0.36      |
| Pre transfusion haemoglobin level (g/dL) | 7.53±1.62                                         | 8.34±0.98                                               | 0.27      |
| Deferisirox dose (mg/kg/day)       | 23.04±5.38                                        | 22.05±4.09                                              | 0.40      |
| Mean serum ferritin level          | 3438.00±1699.08                                   | 2850.8±1442.76                                         | 0.29      |

*Significant at p = 0.001
*Mann–Whitney U test

RESULTS

Forty patients suffering from beta thalassemia major and thirty age and sex matched healthy individuals were included in the study. The male female ratio of the study group is 82:100 and the control group was 87.5:100. The mean ages of the patient group and control group were 11 ± 6 and 13 ± 6, respectively.

The commonest endocrine complication in the study group was delayed puberty. Out of 17 patients 53% showed delayed puberty. 71.4% of boys above 14 years showed pubertal delay (n = 5, 71.4%). Among females above 13 years 40% showed delayed puberty (n = 4, 40%).

Hypothyroidism was present in 4 (10%) patients. Diabetes mellitus was reported in 2 (5%) patients. Hypoparathyroidism was reported in 1 (2.5%) patient. There was a significant relationship between endocrine complications with the age and the period under of blood transfusion of the patients at p-value 0.05. Blood transfusion volume (mL/kg/year), mean pretransfusion hemoglobin concentration and deferasirox dose bear no relationship with endocrine complications (Table 1).

In this study, it was found that the mean Z-score for height is –2.3±1.06 (range –0.75 to 5.06). Out of 40 patients, 20(50%) were stunted (Z-score for height <−2 SD) and 10(25%) of them were severely stunted (Z-score for height <−3 SD). A total of 20(50%) patients were of normal height (Z-score for height ≥−2 SD) (Table 2).

The mean Z-score for BMI is –1.32 ± 1.28 (range 0.88 to –3.82). Out of 40 thalassemia patients, 14 (35%) were wasted (Z-score for BMI <−2 SD) and 3(7.5%) of them were severely wasted (Z-score for BMI <−3 SD). 3(7.5%) patients were of normal BMI (Z-score for BMI ≥−2 SD) (Table 2).

The prevalence of wasting and stunting among children of 5–18 years old is 26.7% and 13.1%, respectively [20].
Therefore, the prevalence of wasting and stunting is significantly high among the beta thalassemia major patients when compared to the normal population (p < 0.001).

The majority of the patients (n = 27, 67.5%) were with mid-upper arm circumference (MUAC) less than 5th percentile while none of them had MUAC exceeding a 50th percentile. The percentage of patients with MUAC below 5th percentile was higher among older children (>10 years) (66.7%) than younger patients (<10 years) (33.3%).

Z-score for height bear significant negative correlation with age of the patients (p = 0.02). There was no significant correlation between Z-score for BMI and age of the patients (p = 0.17). Z-score values for height bears significant negative correlation with period under blood transfusion therapy and blood its volume (Table 4). However, pretransfusion hemoglobin level and deferasirox dose bear no significant correlation with growth parameters (Tables 4 and 5). Although Z-score values for height had obvious negative relationship with serum ferritin concentration, it was not statistically significant.

**DISCUSSION**

Endocrine dysfunction is a common secondary complication that is associated with substantial morbidities and mortalities among beta-thalassemia major patients [10]. In our study, it was evident that the occurrence of endocrine complications was obviously related to the advancement of age (>10 years old).

| Age (years) | Height for age | BMI for age |
|-------------|----------------|-------------|
|             | Normal | Mild stunting | Moderate stunting | Severe stunting | Total |
| <5          | 5 (71.4%) | 0 (0%) | 1 (14.3%) | 1 (14.2%) | 7 |
| 5–10        | 6 (50%) | 3 (25%) | 1 (8.3%) | 2 (16.7%) | 12 |
| >10         | 9 (42.9%) | 3 (14.3%) | 2 (9.5%) | 7 (33.3%) | 21 |
| Total       | 20     | 6      | 4       | 10      | 40  |

Therefore, the prevalence of wasting and stunting is significantly high among the beta thalassemia major patients when compared to the normal population (p < 0.001).

The majority of the patients (n = 27, 67.5%) were with mid-upper arm circumference (MUAC) less than 5th percentile while none of them had MUAC exceeding a 50th percentile. The percentage of patients with MUAC below 5th percentile was higher among older children (>10 years) (66.7%) than younger patients (<10 years) (33.3%).

Z-score for height bear significant negative correlation with age of the patients (p = 0.02). There was no significant correlation between Z-score for BMI and age of the patients (p = 0.17). Z-score values for height bears significant negative correlation with period under blood transfusion therapy and blood its volume (Table 4). However, pretransfusion hemoglobin level and deferasirox dose bear no significant correlation with growth parameters (Tables 4 and 5). Although Z-score values for height had obvious negative relationship with serum ferritin concentration, it was not statistically significant.

**DISCUSSION**

Endocrine dysfunction is a common secondary complication that is associated with substantial morbidities and mortalities among beta-thalassemia major patients [10]. In our study, it was evident that the occurrence of endocrine complications was obviously related to the advancement of age (>10 years old).

Similarly, a group of Italian researchers has found that the majority of the patients with endocrine disorders were in their second and third decades of life [12]. This might be related to iron toxicity to endocrine organs due to the progression of iron deposition. Therefore evaluation of endocrine function in the second decade of life is mandatory in beta thalassemia major patients.
According to our study, 50% of the patients were stunted. Our results were with the agreement of studies conducted in Iran and Egypt which reported 49% and 46% of stunting respectively [21, 22]. Short stature showed a significant negative correlation with the age of the patients. In our study, it was revealed that 37% of the patients were wasted. A similar study from Egypt revealed that 30% of the beta-thalassemia major patients were having significantly low BMI levels [21]. Further, our results have shown that low BMI values of the patients were not associated with either the age of the patients or high serum ferritin levels. Similarly, a study from India revealed that there is no correlation between physical growth and serum ferritin levels [23]. The majority of the patients (67.5%) were having MUAC less than <5th percentile. Therefore, according to MUAC the percentage of patients with malnutrition in this study group was low when compared to other studies

Ten percent of patient in this study were affected by Hypothyroidism compared to 17–18% in Iran [29] and 9% in North America [30].

Hypoparathyroidism which is a well-recognized endocrine abnormality in beta-thalassemia major disease was observed in only one patient (2.5%) in our study group. Our findings were consistent with the prevalence observed by Gabutti and Piga [31]. However, the percentage of patients with hypoparathyroidism in this study group was low when compared to other studies conducted in Oman and Iran which reported a prevalence of 14.6% and 19% respectively [32, 33].

Diabetes mellitus was observed in 5% of the patients in the study group. The prevalence of diabetes in this study group is consistent with the rate observed by Borgna-Pignatti et al. in an Italian cohort of patients [34]. A higher rate of diabetes (20%) is reported by Brittenham and coworkers [35].

The overall prevalence of endocrine complications in this study group is low when compared with regional and international studies. The mean age of the patients in our study group (10.97±5.9) is significantly less when compared to other studies. Moreover, all the patients were in their first and second decades of life. However, the development of endocrine dysfunction is associated with the progression of accumulation of iron in the endocrine glands with the advancement of age. Therefore, the low prevalence may be due to the young age of our patients. Furthermore, most of the other studies involved large cohort of the patients but in this study small number of patients were assessed. Variations in the rate of prevalence of endocrinopathies in different cohorts of patients might be due to differences in health care standards and genetic makeup.

In this study, it was found that endocrine complications did not bear any significant association with iron overload. Our findings were consistent with studies that have reported no relation between the iron overload and endocrinopathies [19, 36, 37]. Therefore, endocrinopathies among thalassemia patients might be due to a combination of factors such as iron toxicity, chronic anemia and liver damage due to viral infections. Moreover, endocrine organ damage is caused by prolonged exposure of iron overload but the serum ferritin level indicates iron overload only in the last three months. Therefore, the serum ferritin levels is not an accurate indicator to assess the association between iron overload and endocrine organ dysfunction. In contrast, some researchers have found a significant relationship between endocrinopathies and serum ferritin level [8, 38, 39].

CONCLUSION

Routine assessment of endocrine functions is imperative in beta-thalassemia major patients after the age of 10 years. Moreover, adequate compliance to iron chelation therapy and maintenance of iron stores at safe levels is mandatory.

REFERENCES

1. de Silva S, Fisher CA, Premawardhena A, et al. Thalassaemia in Sri Lanka: Implications for the future health burden of Asian populations. Sri Lanka Thalassaemia Study Group. Lancet 2003;335(9206):786–91.

2. Weatherall DJ, Clegg B. Inherited haemoglobin disorders: An increasing global health problem. Bull World Health Organ 2001;79(8):704–12.

3. Sri Lanka Annual Health Bulletin 1996. Available at: http://ghdx.healthdata.org/record/sri-lanka-annual-health-bulletin-1996

4. Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: A literature review. Transfusion 2007;47(10):1919–29.

5. Riaz H, Riaz T, Khan MU, et al. Serum ferritin levels, socio-demographic factors and desferrioxamine therapy in multi-transfused thalassemia major patients at a government tertiary care hospital of Karachi, Pakistan. BMC Res Notes 2011;4:287.

6. Eissa DS, El-Gamal RA. Iron overload in transfusion-dependent β-thalassemia patients: Defining parameters of comorbidities. Egypt J Haematol 2014;39(3):164–70.

7. De Sanctis V, Soliman AT, Elsedfy H, et al. Growth and endocrine disorders in thalassemia: The international network on endocrine complications in thalassemia
24. Gunarsih A, Amalia P, Baediman I. Variables associated with malondialdehyde level in thalassemia major patients. Paediatr Indones 2012;52(3):125–31.
25. Arijanty L, Nasar SS, Madiyono B, Gatot D. Relationships between plasma zinc and ferritin with nutritional status in thalassemic children. Pediatr Indones 2006;46:220–4.
26. Kumari V, Upadhayay SK, Gupta V, Piplani KS, Bhattia BD. Growth retardation and malnutrition in children with thalassemia major. Indian J Prev Soc Med 2012;43(2):149–51.
27. Joshi R, Phatarpekar A. Endocrine abnormalities in children with Beta thalassemia major. Sri Lanka Journal of Child Health 2013;42(2):81–6.
28. Najafipour F, Aliasgarzadeh A, Aghamohamadzadeh N, et al. A cross-sectional study of metabolic and endocrine complications in beta-thalassemia major. Ann Saudi Med 2008;28(5):361–6.
29. Karamifar H, Shahriari M, Sadjadi N. Prevalence of endocrine complications in beta-thalassemia major in the Islamic Republic of Iran. East Mediterr Health J 2003;9(1-2):55–60.
30. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR; Thalassemia Clinical Research Network. Complications of beta-thalassemia major in North America. Blood 2004;104(1):34–9.
31. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996;95(1):26–36.
32. Sleem GA, Al-Zakwani IS, Almuslami M. Hypoparathyroidism in adult patients with beta-thalassemia major. Sultan Qaboos Univ Med J 2007;7(3):215–8.
33. Hamidieh AA, Moradbeag B, Pasha F, Jalili M. High prevalence of hypoparathyroidism in patients with beta-thalassemia major. Int J Hematol Oncol Stem Cell Res 2009;3(3):17–20.
34. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Survival and complications in thalassemia. Ann N Y Acad Sci 2005;1054:40–7.
35. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331(9):567–73.
36. Masala A, Meloni T, Galliss D, et al. Endocrine functioning in multitransfused prepubertal patients with homozygous beta-thalassemia. J Clin Endocrinol Metab 1984;58(4):667–70.
37. Zervas A, Katopodi A, Protonotarioi A, et al. Assessment of thyroid function in two hundred patients with beta-thalassemia major. Thyroid 2002;12(2):151–4.
38. Gamberrini MR, De Saneti V, Gilli G. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: Incidence and prevalence related to iron overload and chelation therapy in patients with thalassemia major followed from 1980 to 2007 in the Ferrara Centre. Pediatr Endocrinol Rev 2008;6 Suppl 1:158–69.
39. Belhoul KM, Bakir ML, Kadhim AM, Dewedar HE, Eldin MS, Alkhaja FA. Prevalence of iron overload complications among patients with beta-thalassemia major treated at Dubai Thalassemia Centre. Ann Saudi Med 2013;33(1):18–21.

**********
Acknowledgments
We would like to thank Mr. JMNS Nawaratna, Mr. CN Perera, AMPSTM Bandara, and Mrs. PC Rajakaruna for their assistance in sample collection and laboratory analysis. Further our thanks go to Director and staff members of Peradeniya Teaching Hospital.

Author Contributions
Attanayaka Mudiyanselage Dilhara Sewwandi Karunaratna – Conception of the work, Design of the work, Acquisition of data, Analysis of data, Interpretation of data, Drafting the work, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved
Jamburagoda Gamage Shirani Ranasingha – Conception of the work, Design of the work, Analysis of data, Interpretation of data, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved
Rasnayaka Mudiyanselage Mudiyanse – Conception of the work, Design of the work, Acquisition of data, Analysis of data, Interpretation of data, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

Guarantor of Submission
The corresponding author is the guarantor of submission.

Source of Support
None.

Consent Statement
Written informed consent was obtained from the patient for publication of this article.

Conflict of Interest
Authors declare no conflict of interest.

Data Availability
All relevant data are within the paper and its Supporting Information files.

Copyright
© 2020 Attanayaka Mudiyanselage Dilhara Sewwandi Karunaratna et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
